Compare Moderna, Inc. (MRNA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Vanguard Total International Stock Index Fund ETF trades at $84.5. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | VXUS | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $81.80 | $87.06 |
52-Week Low | $22.36 | $68.24 |
Enterprise Value | $19.70B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
